Blar i NTNU Open på forfatter "Meyer, Peter Albert"

Viser treff 1-2 av 2

    • Patients with high-risk DLBCL benefit from dose-dense immunochemotherapy combined with early systemic CNS prophylaxis 

      Leppä, Sirpa; Jørgensen, Judit; Tierens, Anne; Meriranta, Leo; Østlie, Ingunn; Brown, Peter de Nully; Fagerli, Unn-Merete; Larsen, Thomas Stauffer; Mannisto, Susanna; Munksgaard, Lars; Maisenhölder, Martin; Vasala, Kaija; Meyer, Peter Albert; Jerkeman, Mats; Björkholm, Magnus; Fluge, Øystein; Jyrkkiö, Sirkku; Liestøl, Knut; Ralfkiaer, Elisabeth; Spetalen, Signe; Beiske, Klaus; Karjalainen-Lindsberg, Marja-Liisa; Holte, Harald (Peer reviewed; Journal article, 2020)
      Survival of patients with high-risk diffuse large B-cell lymphoma (DLBCL) is suboptimal, and the risk of central nervous system (CNS) progression is relatively high. We conducted a phase 2 trial in 139 patients aged 18 to ...

    • Rituximab-treated patients with lymphoma develop strong CD8 T-cell responses following COVID-19 vaccination 

      Riise, Jon; Meyer, Saskia; Blaas, Isaac; Chopra, Adity; Tran, Trung; Delic-Sarac, Marina; Hestdalen, Malu Lian; Brodin, Ellen Elisabeth; Rustad, Even Holth; Dai, Ke-Zheng; Vaage, John T.; Nissen-Meyer, Lise Sofie Haug; Sund, Fredrik; Wader, Karin Fahl; Bjørnevik, Anne Turid; Meyer, Peter Albert; Nygaard, Gro Owren; König, Marton; Smeland, Sigbjørn; Lund-Johansen, Fridtjof; Olweus, Johanna; Kolstad, Arne (Peer reviewed; Journal article, 2022)
      B-cell depletion induced by anti-cluster of differentiation 20 (CD20) monoclonal antibody (mAb) therapy of patients with lymphoma is expected to impair humoral responses to severe acute respiratory syndrome coronavirus-2 ...